CN105658221B - 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 - Google Patents

用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 Download PDF

Info

Publication number: CN105658221B
Authority: CN; China
Prior art keywords: alpha; atrophic; skin; pharmaceutical composition; pgf
Prior art date: 2013-09-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN201480053306.1A

Other languages

English (en)

Chinese (zh)

Other versions

CN105658221A (zh

Inventor

沃伦·J·舍雷尔

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Galderma SA

Original Assignee

Galderma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-26

Filing date

2014-09-26

Publication date

2022-05-10

2014-09-26 Application filed by Galderma SA filed Critical Galderma SA

2016-06-08 Publication of CN105658221A publication Critical patent/CN105658221A/zh

2022-05-10 Application granted granted Critical

2022-05-10 Publication of CN105658221B publication Critical patent/CN105658221B/zh

Status Expired - Fee Related legal-status Critical Current

2034-09-26 Anticipated expiration legal-status Critical

Links

238000011282 treatment Methods 0.000 title claims description 28
229960001342 dinoprost Drugs 0.000 title 1
PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 title 1
230000037390 scarring Effects 0.000 claims abstract description 30
206010040799 Skin atrophy Diseases 0.000 claims abstract description 18
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims abstract description 11
PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 claims abstract description 6
231100000241 scar Toxicity 0.000 claims description 63
239000000203 mixture Substances 0.000 claims description 62
102000008186 Collagen Human genes 0.000 claims description 34
108010035532 Collagen Proteins 0.000 claims description 34
229920001436 collagen Polymers 0.000 claims description 34
210000002950 fibroblast Anatomy 0.000 claims description 34
239000000499 gel Substances 0.000 claims description 23
239000008194 pharmaceutical composition Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 13
239000002674 ointment Substances 0.000 claims description 12
210000001519 tissue Anatomy 0.000 claims description 12
239000000839 emulsion Substances 0.000 claims description 11
239000000945 filler Substances 0.000 claims description 11
238000009093 first-line therapy Methods 0.000 claims description 11
230000001800 adrenalinergic effect Effects 0.000 claims description 10
230000037311 normal skin Effects 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 10
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 9
238000002647 laser therapy Methods 0.000 claims description 9
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical group CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 8
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims description 8
230000007704 transition Effects 0.000 claims description 8
229960002368 travoprost Drugs 0.000 claims description 8
MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 8
PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims description 7
206010015150 Erythema Diseases 0.000 claims description 7
241000282414 Homo sapiens Species 0.000 claims description 7
231100000321 erythema Toxicity 0.000 claims description 7
230000004761 fibrosis Effects 0.000 claims description 7
229960001160 latanoprost Drugs 0.000 claims description 7
GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
229960001094 midodrine Drugs 0.000 claims description 7
230000000475 sunscreen effect Effects 0.000 claims description 7
239000000516 sunscreening agent Substances 0.000 claims description 7
206010016654 Fibrosis Diseases 0.000 claims description 6
229960002470 bimatoprost Drugs 0.000 claims description 6
AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
229920001296 polysiloxane Polymers 0.000 claims description 6
229960004458 tafluprost Drugs 0.000 claims description 6
WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 6
239000003981 vehicle Substances 0.000 claims description 6
XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 5
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
229960003679 brimonidine Drugs 0.000 claims description 5
238000007906 compression Methods 0.000 claims description 5
230000006835 compression Effects 0.000 claims description 5
229960005192 methoxamine Drugs 0.000 claims description 5
229960005016 naphazoline Drugs 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 5
238000002054 transplantation Methods 0.000 claims description 5
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 5
239000003906 humectant Substances 0.000 claims description 4
230000006872 improvement Effects 0.000 claims description 4
239000002502 liposome Substances 0.000 claims description 4
229960001528 oxymetazoline Drugs 0.000 claims description 4
229960001802 phenylephrine Drugs 0.000 claims description 4
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 4
229960000337 tetryzoline Drugs 0.000 claims description 4
206010003694 Atrophy Diseases 0.000 claims description 3
230000037444 atrophy Effects 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
239000002077 nanosphere Substances 0.000 claims description 3
238000013268 sustained release Methods 0.000 claims description 3
239000012730 sustained-release form Substances 0.000 claims description 3
210000001691 amnion Anatomy 0.000 claims description 2
VFRCNXKYZVQYLX-UHFFFAOYSA-N deglymidodrine Chemical compound COC1=CC=C(OC)C(C(O)CN)=C1 VFRCNXKYZVQYLX-UHFFFAOYSA-N 0.000 claims description 2
230000002829 reductive effect Effects 0.000 claims description 2
101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 claims 2
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
238000004299 exfoliation Methods 0.000 claims 1
229960000833 xylometazoline Drugs 0.000 claims 1
230000000699 topical effect Effects 0.000 abstract description 37
238000000034 method Methods 0.000 abstract description 24
230000001225 therapeutic effect Effects 0.000 abstract description 2
210000003491 skin Anatomy 0.000 description 33
OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 32
208000032544 Cicatrix Diseases 0.000 description 26
230000037387 scars Effects 0.000 description 26
239000004155 Chlorine dioxide Substances 0.000 description 16
235000019398 chlorine dioxide Nutrition 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
230000037319 collagen production Effects 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 12
208000027418 Wounds and injury Diseases 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 8
230000006378 damage Effects 0.000 description 8
208000014674 injury Diseases 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
239000003755 preservative agent Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229920002125 Sokalan® Polymers 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000006071 cream Substances 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
239000003349 gelling agent Substances 0.000 description 6
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
241000282412 Homo Species 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
239000000048 adrenergic agonist Substances 0.000 description 5
239000003963 antioxidant agent Substances 0.000 description 5
235000006708 antioxidants Nutrition 0.000 description 5
239000000872 buffer Substances 0.000 description 5
229960001631 carbomer Drugs 0.000 description 5
230000001969 hypertrophic effect Effects 0.000 description 5
-1 mido Jun Chemical compound 0.000 description 5
239000003921 oil Substances 0.000 description 5
208000002260 Keloid Diseases 0.000 description 4
206010039580 Scar Diseases 0.000 description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003974 emollient agent Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000001117 keloid Anatomy 0.000 description 4
238000013532 laser treatment Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000008733 trauma Effects 0.000 description 4
208000002874 Acne Vulgaris Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
206010023330 Keloid scar Diseases 0.000 description 3
239000004372 Polyvinyl alcohol Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010000496 acne Diseases 0.000 description 3
239000004037 angiogenesis inhibitor Substances 0.000 description 3
230000000507 anthelmentic effect Effects 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000000835 fiber Substances 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
229960005150 glycerol Drugs 0.000 description 3
239000010954 inorganic particle Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000006210 lotion Substances 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920002451 polyvinyl alcohol Polymers 0.000 description 3
235000019422 polyvinyl alcohol Nutrition 0.000 description 3
230000003716 rejuvenation Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
235000002961 Aloe barbadensis Nutrition 0.000 description 2
244000186892 Aloe vera Species 0.000 description 2
102100035991 Alpha-2-antiplasmin Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000010032 Calcium-Independent Phospholipases A2 Human genes 0.000 description 2
108010077241 Calcium-Independent Phospholipases A2 Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
101000783712 Homo sapiens Alpha-2-antiplasmin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
239000004909 Moisturizer Substances 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
102000000471 Prostaglandin F receptors Human genes 0.000 description 2
108050008995 Prostaglandin F receptors Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
235000011399 aloe vera Nutrition 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000921 anthelmintic agent Substances 0.000 description 2
229940124339 anthelmintic agent Drugs 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001333 moisturizer Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229920001432 poly(L-lactide) Polymers 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002206 pro-fibrotic effect Effects 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
239000004034 viscosity adjusting agent Substances 0.000 description 2
YHHHHJCAVQSFMJ-FNORWQNLSA-N (3e)-deca-1,3-diene Chemical compound CCCCCC\C=C\C=C YHHHHJCAVQSFMJ-FNORWQNLSA-N 0.000 description 1
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
208000018380 Chemical injury Diseases 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
206010050207 Skin fibrosis Diseases 0.000 description 1
206010040867 Skin hypertrophy Diseases 0.000 description 1
208000028990 Skin injury Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
244000028419 Styrax benzoin Species 0.000 description 1
235000000126 Styrax benzoin Nutrition 0.000 description 1
235000008411 Sumatra benzointree Nutrition 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000002679 ablation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
229940037003 alum Drugs 0.000 description 1
229940009827 aluminum acetate Drugs 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
229960002130 benzoin Drugs 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
229910001919 chlorite Inorganic materials 0.000 description 1
229910052619 chlorite group Inorganic materials 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940061631 citric acid acetate Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010410 dusting Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
235000019382 gum benzoic Nutrition 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000003810 hyperpigmentation Effects 0.000 description 1
208000000069 hyperpigmentation Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
208000011379 keloid formation Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
VLUXBNSRYHXDBV-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-4,5-dihydro-1,3-thiazol-2-amine Chemical compound CC1=CC=CC(C)=C1NC1=NCCS1 VLUXBNSRYHXDBV-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000004493 normal intraocular pressure Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
210000001626 skin fibroblast Anatomy 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000037072 sun protection Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
239000012929 tonicity agent Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
239000011667 zinc carbonate Substances 0.000 description 1
235000004416 zinc carbonate Nutrition 0.000 description 1
229910000010 zinc carbonate Inorganic materials 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
229960001296 zinc oxide Drugs 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dispersion Chemistry (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
External Artificial Organs (AREA)

CN201480053306.1A 2013-09-26 2014-09-26 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 Expired - Fee Related CN105658221B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361960740P	2013-09-26	2013-09-26
US61/960,740		2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en)	2013-09-26	2014-09-26	Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (2)

Publication Number	Publication Date
CN105658221A CN105658221A (zh)	2016-06-08
CN105658221B true CN105658221B (zh)	2022-05-10

Family

ID=52282772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201480053306.1A Expired - Fee Related CN105658221B (zh)	2013-09-26	2014-09-26	用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物

Country Status (11)

Country	Link
US (1)	US10039770B2 (ru)
EP (1)	EP3049088B1 (ru)
JP (1)	JP6453318B2 (ru)
KR (1)	KR102221499B1 (ru)
CN (1)	CN105658221B (ru)
AU (1)	AU2014326298B2 (ru)
BR (1)	BR112016006426A2 (ru)
CA (1)	CA2924460A1 (ru)
MX (1)	MX374476B (ru)
RU (1)	RU2690183C2 (ru)
WO (1)	WO2015044788A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017007910A1 (en) *	2015-07-09	2017-01-12	Galderma S.A.	Method of reducing hair loss associated with chemotherapy
CN106929477B (zh) *	2017-03-20	2020-01-10	江南大学	一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3278447A (en)	1963-12-02	1966-10-11	Cloro Bac Products Inc	Process for stabilizing chlorine dioxide solution
IL92351A (en)	1988-11-29	1994-02-27	Allergan Inc Irvine	Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5736165A (en)	1993-05-25	1998-04-07	Allergan	In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en)	1995-06-28	2001-02-27	Allergan Sales, Inc.	Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) *	1999-05-24	2003-01-10	Парамонов Борис Алексеевич	Способ дермабразии
US6468989B1 (en)	2000-07-13	2002-10-22	Dow Pharmaceutical Sciences	Gel compositions containing metronidazole
US6387383B1 (en)	2000-08-03	2002-05-14	Dow Pharmaceutical Sciences	Topical low-viscosity gel composition
US7405274B2 (en) *	2003-06-04	2008-07-29	Fibrogen, Inc.	Connective tissue growth factor antibodies
EP2278993A4 (en) *	2008-05-16	2012-09-12	Corthera Inc	METHOD FOR PROMOTING HEALING
EP2389939A1 (en) *	2010-05-28	2011-11-30	Novagali Pharma S.A.	Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) *	2010-08-24	2011-04-27	苏州圣诺生物医药技术有限公司	促进皮肤伤口无疤痕愈合的siRNA及应用
BR112013014021A8 (pt) *	2010-12-06	2017-10-03	Follica Inc	Métodos para tratamento de calvície e promoção de crescimento de cabelos
JP6017455B2 (ja) *	2011-01-31	2016-11-02	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	毛髪成長を増強する方法
US20120251613A1 (en) *	2011-03-29	2012-10-04	Agila Specialities Pvt. Ltd.	Method for treating vitiligo with a prostaglandin analogue
WO2014179263A1 (en) *	2013-04-30	2014-11-06	Allergan, Inc.	Therapeutic agents

2014
- 2014-09-26 CN CN201480053306.1A patent/CN105658221B/zh not_active Expired - Fee Related
- 2014-09-26 RU RU2016110925A patent/RU2690183C2/ru active
- 2014-09-26 WO PCT/IB2014/002746 patent/WO2015044788A1/en active Application Filing
- 2014-09-26 EP EP14824091.4A patent/EP3049088B1/en active Active
- 2014-09-26 US US15/021,789 patent/US10039770B2/en active Active
- 2014-09-26 BR BR112016006426A patent/BR112016006426A2/pt active Search and Examination
- 2014-09-26 CA CA2924460A patent/CA2924460A1/en not_active Abandoned
- 2014-09-26 AU AU2014326298A patent/AU2014326298B2/en not_active Ceased
- 2014-09-26 JP JP2016517505A patent/JP6453318B2/ja not_active Expired - Fee Related
- 2014-09-26 KR KR1020167010897A patent/KR102221499B1/ko not_active Expired - Fee Related
- 2014-09-26 MX MX2016003650A patent/MX374476B/es active IP Right Grant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Repigmentation of Hypopigmented Scars Using an Erbium-Doped 1,550-nm Fractionated Laser and Topical Bimatoprost;ANE BEATRIZ MAUTARI NIWA MASSAKI等;《DERMATOLOGIC SURGERY》;20121231;第38卷;第995–1001页 *

Also Published As

Publication number	Publication date
AU2014326298A1 (en)	2016-04-07
JP6453318B2 (ja)	2019-01-16
RU2016110925A (ru)	2017-11-01
KR20160055941A (ko)	2016-05-18
MX374476B (es)	2025-03-06
JP2016531872A (ja)	2016-10-13
KR102221499B1 (ko)	2021-03-02
US10039770B2 (en)	2018-08-07
RU2690183C2 (ru)	2019-05-31
BR112016006426A2 (pt)	2017-08-01
EP3049088B1 (en)	2021-02-17
WO2015044788A1 (en)	2015-04-02
CN105658221A (zh)	2016-06-08
RU2016110925A3 (ru)	2018-07-13
CA2924460A1 (en)	2015-04-02
US20160228453A1 (en)	2016-08-11
EP3049088A1 (en)	2016-08-03
AU2014326298B2 (en)	2019-07-04
MX2016003650A (es)	2016-06-24

Publication	Publication Date	Title
JP6966455B2 (ja)	2021-11-17	侵襲的且つ非侵襲的な処置上のスキンケアのための組成物及び方法
US7833542B2 (en)	2010-11-16	Method and composition for the treatment of scars
AU2008341112B2 (en)	2014-02-06	Pre-surgical treatment
US9962402B2 (en)	2018-05-08	Healing composition for topical application
JP2012528132A (ja)	2012-11-12	注射による皮膚反応を減少させるための、アドレナリン受容体アゴニストと充填剤との注射可能な組合せ
EA024483B1 (ru)	2016-09-30	Местная композиция для лечения гиперкератотической кожи
KR20150047505A (ko)	2015-05-04	건선 치료용 조성물
JP2014518239A (ja)	2014-07-28	皮膚反応を低減するための新規な安定麻酔組成物
CN105658221B (zh)	2022-05-10	用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物
JP7570334B2 (ja)	2024-10-21	化粧品／皮膚科用組成物
US10076558B2 (en)	2018-09-18	Prophylactic normalization of cutaneous wound repair
JP2014530847A (ja)	2014-11-20	毛細血管腫の治療方法
JP2023545070A (ja)	2023-10-26	皮膚バリアに影響を及ぼす皮膚科学的処置における治療的皮膚治療のための方法および組成物
US20210177740A1 (en)	2021-06-17	Transpore delivery of cannabinoid and uses thereof
JP2024516316A (ja)	2024-04-12	萎縮性瘢痕を治療するためのキヌレニンおよびその誘導体
CN113272020A (zh)	2021-08-17	具有抗真菌特性的指甲组合物
US20190021995A1 (en)	2019-01-24	Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
US20200030264A1 (en)	2020-01-30	Topical anesthetic for use with laser radiation and methods of forming same
MX2013001099A (es)	2014-07-28	Crema o gel de aplicación tópica con neurotoxina botulinica encapsulada en nanoparticulas liposomales para el tratamiento de la hiperhidrosis.

Legal Events

Date	Code	Title	Description
2016-06-08	C06	Publication
2016-06-08	PB01	Publication
2016-07-06	C10	Entry into substantive examination
2016-07-06	SE01	Entry into force of request for substantive examination
2022-05-10	GR01	Patent grant
2022-05-10	GR01	Patent grant
2024-09-27	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20220510
2024-09-27	CF01	Termination of patent right due to non-payment of annual fee